Study of LATS2 in Nasopharyngeal Carcinoma Uses Hettich ROTOFIX 32



Application Search

Study of LATS2 in Nasopharyngeal Carcinoma Uses Hettich ROTOFIX 32

Study of LATS2 in Nasopharyngeal Carcinoma Uses Hettich ROTOFIX 32

BioMed Central published a study entitled “LATS2 is De-methylated and Overexpressed in Nasopharyngeal Carcinoma and Predicts Poor Prognosis” that investigates the role of LATS2 in nasopharyngeal carcinoma. Researchers used the Hettich ROTOFIX 32 to understand the effect of LATS2 on cell survival via its expression pattern and clinicopathological involvement in nasopharyngeal carcinoma.

LATS2 encodes serine/threonine kinase and is vital in centrosome duplication and maintenance of genomic stability. In recent years, LATS2 mRNA has been reported to suppress tumors in breast cancer and acute lymphoblastic leukemia (ALL). However, according to the study, the enzyme’s effects in nasopharyngeal carcinoma have yet to be observed.

The study makes use of quantitative real time PCR and immunoblotting to detect the expression of LATS2 in nasopharyngeal carcinoma cell lines and in the immortalized nasopharyngeal epithelial cell line NP69. 220 nasopharyngeal carcinoma cases were then analyzed for the protein expression using immunohistochemistry. The cultured cells were harvested and washed three times with PBS. They were then re-suspended with PBS and centrifuged with the Hettich ROTOFIX 32.

Results from the experiment indicate that LATS2 played a potential role in the tumorigenesis of nasopharyngeal carcinoma by promoting cell growth. The researchers concluded that transfection with specific siRNA could potentially inhibit growth, induce apoptosis and increase S phase in nasopharyngeal carcinoma.

Hettich offers a comprehensive range of centrifuges for clinical, research, and industrial applications. The ROTOFIX 32 is a rugged benchtop centrifuge for routine and specialty applications. To find a Hettich centrifuge to fit your application, visit:

Categories: Clinical, Research

Comments (0)

Leave a comment

You are commenting as guest.